EVG Evgen Pharma Plc

 

TIDMEVG TIDMPMR 
 
RNS Number : 1917T 
Evolution Group PLC 
23 September 2010 
 

The Evolution Group Plc 
 
23 September 2010 
 
                            THE EVOLUTION GROUP PLC 
 
For Immediate Release 
 
Evolution Group Plc ("Evolution" or the "Company") 
 
Statement regarding Panmure Gordon & Co plc ("Panmure Gordon"). 
 
The Board of Evolution Group notes the press speculation regarding a possible 
acquisition of Panmure Gordon by the Company. 
 
There has been much speculation about consolidation within the sector in London 
and, in keeping with the Company's publicly stated policy, at any given time the 
Company has under consideration a broad range of options in relation to both its 
fund management and securities businesses, with a view to enhancing shareholder 
value. 
 
The Company confirms that at the current time, one such option is a possible 
offer for Panmure Gordon.  However, it should be emphasised, that the board's 
deliberations in relation to Panmure Gordon are at a very early stage and that 
no formal discussions have taken place between management of the Company and 
Panmure Gordon. The Company is keen to assess Panmure Gordon's upcoming trading 
results before determining whether there is any merit in taking its 
deliberations further. 
 
At this stage, there can be no assurance that any offer will be made. 
 
A further statement will be made as and when appropriate. 
 
For Enquiries: 
 
Evolution 
 
Alex Snow, Chief Executive Officer                              02070714300 
 
Investor Relations 
 
Charles Cooke, Director Merlin Financial                      02077268400 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 SPCBXLFLBKFEBBX 
 

Grafico Azioni Evgen Pharma (LSE:EVG)
Storico
Da Lug 2024 a Ago 2024

Grafico Azioni Evgen Pharma (LSE:EVG)
Storico
Da Ago 2023 a Ago 2024